NCPA’s new chief likely to shift focus to the Hill
ALEXANDRIA, Va. — The natural affinity that has sprung up between independent pharmacy and the generic drug industry — both viewed as underdogs in the relentless fight for market position and profits: one versus powerful chain and big-box retailers, the other versus the far more entrenched and well-funded branded drug industry — was never more fully realized than it was at the end of October, when the National Community Pharmacists Association introduced its new top manager to its members at the group’s annual meeting.
The NCPA’s new EVP and CEO is Kathleen Jaeger, formerly head of the Generic Pharmaceutical Association. Jaeger, a coolly competent industry spearhead and Washington insider, will bring a markedly different leadership style to the independent pharmacy group than that of her predecessor, the able Bruce Roberts, who retired in June. Both are pharmacists; Jaeger, like Roberts, is steeped in the allure of community pharmacy and is the daughter of an independent pharmacist, as well as a pharmacist by training. But where Roberts brought passion borne of long experience operating his own pharmacies to his role as the face of independent pharmacy, Jaeger likely will put a different stamp on the NCPA.
A lawyer as well as a pharmacist by training, Jaeger has the kind of inside-the-Beltway contacts and legal credentials that the organization may need at this stage of its long existence. Before taking command of the GPhA eight years ago, she honed her Washington chops by chairing the Food and Drug Practice for the McKenna and Cuneo law firm and for Kirkpatrick and Lockhart.
While at the GPhA, she worked hard to win respect and visibility for generic drugs and their manufacturers among the public and on Capitol Hill. And that’s exactly the kind of advocacy that the NCPA needs—particularly in this unsettled time of rapid change and uncertainty as the massive reforms coming to the U.S. healthcare system begin to work their way through every facet of professional practice, including pharmacy.
It’s no secret that independent community pharmacies have been hit particularly hard by this brutal recession—not to mention by the longer-term challenges that preceded it, like the steady erosion of pharmacy profit margins. But their role still is a critical one, especially in rural areas where big chains don’t tread. And that’s to say nothing of their economic importance as the small, locally owned businesses that every economy needs in order to thrive.
Jaeger’s experience at the GPhA and as a second-generation pharmacist is a big asset for the NCPA, and if she can replicate her GPhA successes there, then independent pharmacies across the country are likely to benefit as well.
NACDS, NCPA claim pharmacy victory after withdrawal of Medicaid program provisions
ALEXANDRIA, Va. The National Association of Chain Drug Stores and the National Community Pharmacists Association heralded the withdrawal of two provisions from the Medicaid program that would have had retail pharmacies selling generic drugs at a loss.
The Centers for Medicare and Medicaid Services cut provisions that defined average manufacturer price and determined calculation of federal upper limits. The NACDS and NCPA sued CMS in the U.S. District Court for the District of Columbia in November 2007 to obtain an injunction against the provisions, which the court granted. In response, CMS revised its definition of multiple source drugs in October 2008, though the pharmacy lobby groups amended their lawsuit to block that as well, saying it was still against the law. CMS’ new rule removes that provision as well.
In a joint statement, NACDS president and CEO Steve Anderson and NCPA EVP and CEO Kathleen Jaeger heralded the decision, saying the rule would have reduced patients’ access to pharmacies by cutting reimbursements, thus forcing retail pharmacies to sell generic drugs at a loss.
“We insisted that this policy was not appropriate,” the statement read. “Separately, we also have urged that policy-makers should recognize the ability of pharmacies and pharmacists to help improve health and reduce healthcare costs. We are gratified that this sense is reflected in the pharmacy provisions of the new healthcare-reform law. The new law contains provisions ranging from dramatically reducing the [accelerated manufacturing of pharmaceutical] cuts to advancing medication therapy management, through which pharmacists can help patients take their medications correctly, which is referred to as ‘medication adherence.’”
Roadside announces partnership to further ‘drive’ wellness programs
BOSTON Two companies have formed a partnership to provide services for long-haul truck drivers.
Sleep HealthCenters and Roadside Medical Clinic + Lab announced a partnership Wednesday to provide sleep medicine services as part of Roadside’s driver-wellness programs.
Roadside provides medical services, such as Department of Transportation-compliant physicals, drug testing, driver-wellness programs and sleep services for professional drivers on the highway and at company terminals. Sleep HealthCenters will support Roadside’s programs by providing education, professional diagnosis and treatment support, which will be incorporated into the driver-wellness program.
“You cannot effectively screen, test and treat sleep apnea without addressing and improving drivers’ overall health condition, such as weight, [body-mass index], stress and cardiac strength,” Roadside COO Rob Scheschareg said. “By providing continuous care for drivers for sleep, fitness, health and [Department of Transportation] compliance from the terminal to the highways, Roadside Medical is able to move the needle toward better driver health.”